YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Parker Waichman Alonso LLP Headlines by Topic
Procrit
FDA Investigating Procrit and Epogen Following Clinical Trial Deaths
Sep 26, 2008 | Parker Waichman Alonso LLP
Epoetin alfa, an anemia drug sold in the U.S. as Procrit and Epogen, is being reviewed by federal regulators after patients in a German stroke study...
Amgen Ends Controversial Aranesp Marketing Practices
Aug 29, 2008 | Parker Waichman Alonso LLP
The maker of Aranesp is halting marketing practices that critics said encouraged over-use of the anemia drug. Criticism of the policies, in...
More than 44,000 Vials of Procrit Recalled
Aug 6, 2008 | Parker Waichman Alonso LLP
Procrit is being recalled by Johnson & Johnson subsidiary Ortho Biotech. According to the company's recall notice, the action is necessary...
FDA Forces New Labeling for Procrit, Aranesp and Epogen
Jul 31, 2008 | Parker Waichman Alonso LLP
Federal regulators have decided that the anemia drugs Aranesp, Epogen and Procrit need to have additional safety-related changes to their...
Study Says Genetic Tests May Predict if Procrit, Aranesp or Epogen Will Speed Tumor Growth
Jun 3, 2008 | Parker Waichman Alonso LLP
Some cancer patients treated with the anemia drugs Procrit, Aranesp and Epogen could experience increased tumor growth. However, researcher...
Lawmakers Lean on FDA to Police Drug Advertising
May 8, 2008 | Parker Waichman Alonso LLP
Last month, Congress asked the Food and Drug Administration (FDA) to speed its efforts in forcing drug companies to include safety-reporting...
Vytorin, Procrit, Lipitor TV Ads Subject of Congress Probe
May 6, 2008 | Parker Waichman Alonso LLP
A U.S. congressional panel is now examining television ads for cholesterol drugs Lipitor and Vytorin and for the anemia drug Procrit at a Thursday...
Congress Investigates Procrit, Epogen and Aranesp Marketing
Apr 2, 2008 | Parker Waichman Alonso LLP
Two members of Congress are looking into to allegations that the marketing of Procrit, Aranesp and Epogen encouraged overuse of the anemia drugs,...
Procrit, Aranesp, Epogen Should Be Allowed for Cancer Patients, With Some Restrictions, FDA Panel Says
Mar 13, 2008 | Parker Waichman Alonso LLP
An advisory panel has weighed in on the safety issues surrounding Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients and...
Procrit, Aranesp, Epogen Could be Restricted by FDA
Mar 12, 2008 | Parker Waichman Alonso LLP
Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug...
Defective Drugs
